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 Abstract 
Objective: The objective of this selective EBM review is to determine whether or not “Is 
cariprazine effective and safe in treating acute mania in bipolar I disorder?” 
Study Design: This review is based on three double-blind, randomized controlled trials (RCTs) 
published in English, in 2015. These studies compared both the efficacy, safety, and tolerability 
of cariprazine in the treatment of acute mania in bipolar I disorder.  
Data sources: Three double-blind, placebo-controlled, RCTs published in English, in peer-
reviewed journals, and found using Medline, Pubmed, and Cochrane Review databases.  
Outcomes Measured: The primary efficacy scale used in all studies was the Young Mania 
Rating Scale (YMRS) which is a screening tool that objectively and subjectively measures acute 
mania items including: irritability, speech, content, disruptive behavior, elevated mood, 
increased motor activity, sexual interest, sleep, language-though disorder, appearance, and 
insight. Safety was measured through the occurrence of one or more of the following during 
treatment as experienced by the patient: extrapyramidal disorder, headache, akathisia, 
constipation, nausea, dyspepsia, dizziness, insomnia, vomiting, diarrhea, restlessness, sedation, 
vision blurred, mania, pain in extremity, pyrexia, tremor, agitation, or toothache. 
Results: All three studies found cariprazine demonstrated efficacy and general tolerability in the 
treatment of mania in acute bipolar I disorder compared to placebo (p<0.05). The YMRS 
baseline scores compared to week 3 after treatment with carpirazine low dose (3 mg/day) and 
high dose (12 mg/day) were significantly lower than the placebo group (p<0.05) in all three 
studies. According to all three studies the most common treatment related adverse events were: 
akathisia, extrapyramidal symptoms, nausea, and constipation.  
Conclusions: The results based on these three studies is the cariprazine is effective and generally 
well-tolerated for patients experiencing acute mania in bipolar I disorder. Future study is 
warranted to determine the remission rate of manic episodes after treatment with cariprazine for 
bipolar I disorder.  
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Introduction 
 Bipolar I disorder is a mood disorder causing shifts in mood, energy levels, and ability to 
function in daily living that is characterized by both manic and depressive episodes.4,5 These 
manic episodes are characterized by decreased need for sleep, flight of ideas, increase in 
psychomotor agitation, or excessive involvement of pleasurable activities that have high risk of 
consequence for at least 1 week.4,8 Following these manic episodes cycles depressive states of 
decreased pleasure, diminished interest, apathy, and decreased appetite.8 Patients diagnosed with 
bipolar I disorder have may have continued difficulty in psychosocial functioning with daily 
living.5,8 This paper evaluates three randomized controlled studies exploring the efficacy and 
safety of cariprazine, a partial dopamine receptor agonist in treating acute mania in bipolar I 
disorder.  
Bipolar disorder affects 5.7 million American adults, or 2.6% of adults over 18 every 
year.6 The typical age of onset is between 20 and 30 years old, although premorbid symptoms are 
commonly reported in early adolescence.4,8 The prevalence is equal between men and women, 
however men are more prone to manic episodes, while women are susceptible to more 
depressive episodes over respective lifetimes.8 The estimated total healthcare cost of bipolar 
disorder was $45 billion per year in 1991 (the most recent data). Most of the cost was attributed 
to decreased functional capacity and lost work days.7 There is no exact estimate of total 
hospitalizations, but in 2002-2003, the diagnosis of bipolar disorder of youth 19 and younger in 
office visits was 1,003 for every 100,000.5  
The cause of bipolar disorder in currently being studied and is ill-defined. It is believed to 
be multifactorial including: hormone alterations of serotonin and dopamine in the brain, 
hyperexcitability of neuron potentials, genetic, and environmental.4,5 Genetic predispositions 
Reaume Cariprazine Bipolar 2 
play a large role in bipolar I disorder carrying a risk of 80% for monozygotic twins.8 Genome 
studies have identified diacylglycerol kinase (DGKH), ankryin G (ANK3), L-type voltage-gated 
calcium channel (CACNA1C), and a region on chromosome 16p12 as being pertinent to bipolar 
1 disorder.4,8 Environmental factors such as stress, social-behavioral patterns, and increasing 
sympathetic nervous activity have been shown to affect the disease process.4 Elevation of 
cortisol (through stress) impairing hippocampal events decreased limbic activation and 
neurogenesis. In addition, regulation of dopamine in the nucleus accumbens has been associated 
with depressive episodes, while over expression of glycogen synthase kinase in glutamate 
receptors have been associated with manic episodes.8  
 The diagnosis of bipolar I disorder is made on the history and physical exam of the 
patient with one or more manic episodes (lasting at least 1 week) which cycle with depressive 
episodes.4 There is no definitive cure for bipolar I disorder and treatment includes a multi-
modality approach including medication, cognitive-behavioral therapy, and electroconvulsive 
therapy. Acute treatment of manic episodes in bipolar I disorder include: lithium, valproic acid, 
and possibly benzodiazepines (with psychotic symptoms).5,8 Second generation anti-psychotics 
such as olanzapine, risperidone, and quitepaine have also been shown to be effective.4,8 Current 
treatments such as lithium are continually being evaluated because of adverse side effects 
including tremor, hypothyroidism, arrhythmias, seizures and blood monitoring every 4-8 weeks.8 
Bipolar disorder is a complex, multifactorial disease that involves recurrence and variable 
severity of symptoms even with current treatment regimens as listed above. Cariprazine is being 
proposed to safely treat acute mania in bipolar I disorder with positive long term effects on 
quality life.  
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Objective 
 The objective of this selective EBM review is to determine whether or not carpirazine is 
effective and safe in treating acute mania in bipolar I disorder.  
Methods 
 Three double-blind, placebo-controlled, randomized controlled studies were included in 
this systematic review. In all three studies the patient population included male and female adults 
ages 18 to 65 years old with a diagnosis of bipolar I disorder, mixed or manic type, with or 
without psychotic symptoms. These studies used oral cariprazine 3 mg -12 mg per day as the 
intervention. Calabrese et al.1 randomly assigned patients to either cariprazine 3-6 mg per day 
which was considered low dose or 6-12 mg per day which was considered high dose. Durgam et 
al.2 and Sachs et al.3 both initiated patients in the randomized treatment group on cariprazine 1.5 
mg per day and doubled the dosing after day 2, continuing up to a maximum dose of 12 mg per 
day if tolerability and patient response met safety criteria.  
All three studies included a no-drug washout period up to 7 days, a 3-week treatment 
phase, and a 2-week safety follow-up. Patients were randomized to either the cariprazine 
treatment group or the placebo experimental group. The cariprazine group was compared to the 
placebo group in terms of YMRS scores to determine the outcomes of efficacy in treating acute 
mania in bipolar I disorder.1,2,3 The adverse events and safety of cariprazine was also measured 
using subjective symptoms reported by the patient, vital signs, liver function, metabolic 
laboratory data and extrapyramidal symptoms.1,2,3  
Data sources include three peer-reviewed journal articles, published in English in 2015. 
All articles were researched through Medline, Pubmed, and Cochrane Review databases. These 
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articles were chosen based on their clinical relevance to my question and inclusion of POEMS. 
Key words searched in Pubmed included “cariprazine” and “bipolar disorder”.  
Inclusion criteria for all three studies included male and female patients ages 18-65 years 
old with a diagnosis of bipolar I disorder, manic or mixed type, with or without psychotic 
symptoms. Additional inclusion criteria included a YMRS score of ≥ 20, a score of ≥ 4 on at 
least two items: irritability, speech, content, or aggressive behavior, a Montgomery-Asberg 
Depression Rating Scale < 18, and a BMI of 18-40 mg/kg. Exclusion criteria varied slightly 
between studies but generally included pregnant women, positive pregnancy test at screening, 
substance abuse, additional axis I diagnosis, suicide risk, significant medical conditions 
(malignancy, hematologic, endocrine, cardiovascular, respiratory, renal, or hepatic disorders), 
current use of psychotropic medication, patients treated with cariprazine within 90 days of 
screening, patients who received electroconvulsive therapy within 3 months of screening, or a 
history of neuroleptic malignant syndrome.  
Statistics reported in all three studies included relative risk reduction (RRR), absolute risk 
reduction (ARR), numbers needed to treat (NNT), and p-values. Primary statistical analyses were 
performed using mixed-effects model with repeated measures (MMRM), analysis of covariance 
model (ANCOVA), and 2-sded 95% confidence intervals (CI).1,2,3 Table 1 below displays the 
demographics and characteristics of the three studies.  
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Table 1: Demographics & Characteristics of Included Studies 
Study Type # Pts Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Calabrese1 
(2015) 
Double 
blind 
RCT 
497 18-65 
years 
Age 18-
65 years 
with a 
diagnosis 
of bipolar 
I disorder 
First 
manic 
episode, 
additional 
psychiatric 
disorder, 
risk of 
suicide, or 
ECT 
within 3 
months 
127 Cariprazine 
low dose 3-
6mg/d or 
high dose 6-
12mg/d 
orally 
Durgam2 
(2015) 
Double 
blind 
RCT 
236 18-65 
years 
Age 18-
65 years 
with a 
diagnosis 
of bipolar 
I disorder 
First 
manic 
episode, 
additional 
psych 
disorder, 
previous 
treatment 
within 90 
days with 
depot 
neuroleptic 
88 Cariprazine 
3-12mg/d 
orally 
Sachs3 
(2015) 
Double 
blind 
RCT 
312 18-65 
years 
Age 18-
65 years 
with a 
diagnosis 
of bipolar 
I disorder 
Axis I 
diagnosis 
other than 
bipolar I, 
substance 
abuse 
within 3 
months, 
ECT 
within 3 
months or 
cariprazine 
within 10 
years 
98 Cariprazine 
3-12mg/d 
orally 
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Outcomes Measured 
 The three studies measured acute mania signs and symptom improvement using the 
Young Mania Rating Scale (YMRS). The YMRS measures irritability, speech, content, 
disruptive-aggressive behavior, elevated mood, increased motor activity, sexual interest, sleep, 
language-thought process, appearance, and insight through patient report as well as investigator 
observation.1,2,3 These YMRS scores were administered at the beginning of the study (baseline), 
days 3, 5, 7, 10, 14, and 21.1,2,3 The YMRS scores on day 21 were then compared to baseline 
scores in both the placebo and treatment group for efficacy.1,2,3    
 Treatment adverse events were also measured using patient subjective reports, vital signs, 
laboratory parameters, and extrapyramidal symptoms.1,2,3 The treatment adverse events (AE’s) 
measured included headache, akathisia, constipation, nausea, dyspepsia, dizziness, insomnia, 
vomiting, diarrhea, mania, tremor, and agitation.1,2,3 The vital signs measured in Durgam et al.2 
included systolic blood pressure (mm Hg), diastolic blood pressure (mm Hg), pulse (bpm), and 
body weight (kg). Calabrese et al.1 and Sachs et al.3 included these vital signs as well as waist 
circumference (cm). The laboratory values measured at baseline as well as week 3 included total 
cholesterol (mg/dL), LDL (mg/dL), HDL (mg/dL), triglycerides (mg/dL), and glucose (mg/dL) 
in Durgam et al.2 Calabrese et al.1 and Sachs et al.3 also included alanine aminotransferase (U/L), 
aspartate aminotransferase (U/L), total bilirubin (mg/dL), prolactin (ng/dL), and creatine kinase 
(U/L).  
Results 
All three studies reviewed patients ages 18-65 with a diagnosis of bipolar I disorder 
treatment with oral cariprazine 3mg-12mg per day compared to that receiving a placebo. In 
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Calabrese et al.1 there was a total of 497 patients enrolled in the study with the studies being 
performed at 65 different study centers. A total of 48 patients discontinued the study (9%) due to 
adverse events, 25 being the highest in the high dose cariprazine group.1 Patients who were 
experiencing their first manic episode, significant suicidal risk, pregnant, diagnosed with an 
additional axis I disorder, had a substance disorder, significant medical illness, treated with ECT 
within the previous 3 months, or treated with depot neuroleptics within 3 months were excluded 
from this study.1 The patients were enrolled in a 6-week study that included a no-drug washout 
period for up to 7 days, 3 weeks of double-blind treatment, and 2-week safety follow up.1Patients 
were randomly assigned to low dose cariprazine 3-6 mg/day group, high dose cariprazine 6-12 
mg/day group, or a placebo.1 The control event rate (CER) was calculated to be 37.5% in the 
control group and the experimental event rate (EER) was calculated to be 60.6% in the treatment 
group.1 This indicates that 60.6% of the patients receiving cariprazine for treatment of acute 
mania in bipolar I disorder had a ≥ 50% reduction in YMRS scores at week 3 of the study 
compared to the 37.5% in the control group (placebo). The study revealed a relative risk 
reduction (RRR) of 61.6% and an absolute risk reduction (ARR) of 23.1%.1 This indicates that 
patients taking cariprazine had a 61.6% lower risk of developing acute mania and an absolute 
23.1% decrease in acute mania rates compared to the placebo. The number needed to treat 
(NNT) was calculated to be 5 (CI 95%), so for every 5 patients taking cariprazine, 1 patient will 
have a >50% reduction in acute mania in bipolar I disorder.1  
In Sachs et al.2 there was a total of 312 patients enrolled with the studies being performed 
at 38 approved study centers. A total of 98 patients discontinued the study, the majority being 
withdrawal of consent (16.5%) and patients in the placebo group with an insufficient therapeutic 
response (10.4%).2 Patients who were pregnant, had substance abuse disorder, additional axis I 
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diagnosis, had suicide risk, had another significant medical condition, had been treated with 
clozapine within the last 10 years, or received ECT/depot neuroleptic drugs within the last 3 
months were excluded from the study.2 The study included a 3-week, double-blind evaluation of 
patients randomized to either cariprazine 3-12 mg/day (based on tolerability) or placebo to treat 
acute mania.2 The CER was calculated to be 44.1% for the control group and the EER was 
calculated to be 58.9% in the treatment group.2 This indicates that 58.9% of the patients 
receiving cariprazine for treatment of acute mania in bipolar I disorder had a ≥ 50% reduction in 
YMRS scores at week 3 of the study compared to the 44.1% in the control group (placebo). The 
study revealed an RRR of 33.5% and an ARR of 14.8%.2 This indicates that patients taking 
cariprazine had a 33.5% lower risk of developing acute mania and an absolute 14.8% decrease in 
acute mania rates compared to the placebo. The NNT was calculated to be 7 (CI 95%), so for 
every 7 patients taking cariprazine, 1 patient will have a >50% reduction in acute mania in 
bipolar I disorder.2  
In Durgam et al.3 there was a total of 238 patients enrolled in 29 study centers according 
with the Good Clinical Practice guidelines. A total of 88 patients discontinued the study, the 
majority being patients in the placebo group with insufficient therapeutic response (18) and those 
in the treatment group with adverse events (17).3 Patients who were pregnant, had an additional 
axis I disorder, had substance abuse, having their first manic episode, diagnosed with serious 
medical condition (example cardiovascular), had a history of tardive dyskinesia, had neuroleptic 
malignant syndrome, or were treated with a depot neuroleptic/ECT within the last 3 months were 
excluded from the study.3 The study included a 3-week, double-blind evaluation of patients 
randomized to either cariprazine 3-12 mg/day (based on tolerability) or placebo to treat acute 
mania.3 The CER was calculated to be 29.5% for the control group and the EER was calculated 
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to be 49% in the treatment group.3 This indicates that 49% of the patients receiving cariprazine 
for treatment of acute mania in bipolar I disorder had a greater reduction in YMRS scores at 
week 3 of the study compared to the 29.5% in the control group (placebo). The study revealed an 
RRR of 66.1% and an ARR of 19.5%.3 This indicates that patients taking cariprazine had a 
66.1% lower risk of developing acute mania and an absolute 19.5% decrease in acute mania rates 
compared to the placebo. The NNT was calculated to be 5 (CI 95%), so for every 5 patients 
taking cariprazine, 1 patient will have a greater reduction in acute mania in bipolar I disorder.3  
Table 2: Treatment effects of cariprazine for acute mania in bipolar I disorder 
Study P-value/CI CER EER RRR ARR NNT 
Calabrese 
et al.1 
p<0.001/95% 37.5% 60.6% 61.6% 23.1% 5 
Sachs et 
al.2 
p<0.01/95% 44.1% 58.9% 33.5% 14.8% 7 
Durgam et 
al.3 
p<0.001/95% 29.5% 49.0% 66.1% 19.5% 5 
 
In all three studies, cariprazine was generally safe and well-tolerated. In Calabrese et al.1 
there were a total of 10 serious adverse events (SAEs), 3 being in the placebo group and 7 being 
in the low dose cariprazine group. 7 of the 10 SAEs were associated with worsening mania and 
there were no SAEs in the high dose cariprazine group.1 The most common (≥5% in any group) 
treatment-emergent adverse events (TEAEs) in Calabrese et al.1 were akathisia, nausea, 
constipation, and tremor (high dose cariprazine group only). There were no statistically 
significant differences in change from baseline metabolic laboratory parameters or vital signs 
between the treatment and placebo group.1  
In Sachs et al.2 there were a total of 8 patients with SAEs, 3 being in the placebo group 
and 5 being in the treatment group. The only SAE reported in more than one patient was 
worsening of mania (1 in placebo and 2 in the treatment group).2 The only TEAEs that led to 
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discontinuation were worsening of mania, akathisia, and rash (5/2, 0/5, and 2/0 for 
placebo/treatment groups respectively).2 In Sachs et al.2 the mean changes in vital signs and 
metabolic laboratory parameters were small and similar between groups.   
In Durgam et al.3 there were a total of 10 SAEs, 6 being in the placebo group and 4 being 
in the treatment group. The most common SAE was worsening of mania, which occurred in 6 
patients (4 placebo and 2 treatment).3 The most common TEAEs (≥10% of treatment group) 
were extrapyramidal disorder, headache, akathisia, constipation, nausea, and dyspepsia.3 Mean 
changes in vital signs and metabolic laboratory parameters were small and similar between 
groups with the exception of fasting glucose (increase with treatment group, p = 0.04).3 A 
summary of calculated safety and tolerability for all three studies is demonstrated in Table 3.  
Table 3: Safety and tolerability of oral cariprazine for acute mania in bipolar I disorder 
Study Control event 
rate  
(CER) 
Experimental 
event rate 
(EER) 
Relative risk 
reduction 
(RRR) 
Absolute risk 
increase 
(ARI) 
Number 
needed to 
harm (NNH) 
Calabrese et 
al.1 
1.9% 4.2% 121.1% 2.3% 44 
Sachs et al.2 1.3% 0.60% -53.8% -.70% -142.9% 
Durgam et 
al.3 
4.2% 3.4% -19.0% -.80% -125.0% 
 
Discussion 
 Cariprazine is a second generation antipsychotic medication that is a D2, D3, 5-HT1A 
receptor partial agonist and a 5-HT2B receptor partial antagonist.
2 It is mainly used to treat acute 
mania in bipolar I disorder and schizophrenia, but has been used off-label to treat psychosis 
associated with dementia.9 There is a black box warning however, that states cariprazine is not 
approved for dementia related psychosis due to increased mortality with cardiovascular events.9 
The only documented contraindication to cariprazine is hypersensitivity, although multiple 
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cautions are issued including neuroleptic malignant syndrome history, seizure history, 
cerebrovascular disease, cardiovascular disease, hypovolemia, dehydration, diabetes mellitus, 
and leukopenia.9  
 These studies were limited by the lack of a competitive medication, short study duration, 
and adequate measurement of remission rates for acute mania. Although there was significant 
discontinuation among patients in all 3 studies, most were due to insufficient therapeutic 
response or withdrawal of consent in the placebo group. Overall, TEAEs were generally mild 
and similar side effects have been demonstrated in the second generation antipsychotic drug 
class. 
Conclusion 
 This review demonstrated that cariprazine is effective and safe in treating acute mania in 
bipolar I disorder. Cariprazine was associated with a significantly greater reduction in acute 
mania scores compared to placebo after three weeks of treatment in all studies reviewed. TEAEs 
in all three studies were considered mild to moderate in intensity. The tolerability of cariprazine 
was similar with minimal difference in laboratory parameters and vital signs between placebo 
and treatment groups. Future studies are warranted to evaluate the long term outcomes of 
treatment, competitive medication such as another antipsychotic, and accurate measurement of 
remission rates. Studies conducted in the future should consider using a fixed dosing schedule to 
improve efficacy and tolerability interpretations at specific doses of cariprazine. Cariprazine as a 
second generation antipsychotic may continue to improve quality of life as a treatment option for 
bipolar I disorder
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